Global Blood Therapeutics (GBT) Misses Q4 EPS by 23c

Global Blood Therapeutics (NASDAQ: GBT) reported Q4 EPS of ($1.36), $0.23 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $55.44 million.

For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c
• Melco Resorts & Entertainment (MLCO) Misses Q2 EPS by 7c